Pall Onundarson: Diluted Fiix Test Can Be Used to Measure DOACs
Pall Onundarson, Professor Emeritus at Landspitali University Hospital, shared on LinkedIn:
”Diluted Fiix test (dFiix-PT) can be used to measure DOACs.
DOACs were developed to replace VKAs, which were considered difficult to manage because of fluctuating anticoagulant effect measured as PT-INR, commonly attributed to food and drug interactions.
Few considered that the measurement tool itself, the prothrombin time, might have an inherent flaw contributing to variability and amplifying need for dose adjustments.
About 20 years ago, coagulation experts at TandH meetings repeatedly expressed skepticism that oral anticoagulants should be used without monitoring or tailoring.
Nevertheless, DOAC manufacturers conducted RCTs comparing unmonitored DOACs with, in many cases, poorly monitored warfarin, aiming to replace cheap old warfarin entirely.
When results were favorable, DOACs – supported by many key opinion leaders -became first-line for non-valvular AF and most VTE patients and were reimbursed despite higher costs.
At the same time, potential major improvements in warfarin management, such as newer monitoring methods, were largely ignored.
PT-monitored warfarin nevertheless persisted, as it gradually proved superior to DOACs in certain high-risk conditions and remained cheaper, even when monitoring costs were included.
More recently, the need to measure DOAC levels has gained attention, with multiple semi-quantitative and quantitative wet-lab and POC assays described, most far more expensive than the old PT-INR, further increasing DOAC costs.
As many of my LinkedIn contacts know, the Fiix test stabilizes warfarin and appears to reduce thromboembolism substantially compared with PT-INR–monitored warfarin, with proportionally greater benefits than those reported for DOACs versus PT-warfarin.
Our studies have been limited by the small Icelandic population and funding, but Fiix has now shown measurement superiority at a major UK center (personal communication), and a large independent RCT comparing Fiix-warfarin to PT-warfarin in MHV patients is being prepared in North America.
Less well known is that a diluted Fiix test (dFiix-PT), and – less optimally – diluted PT (dPT), can assess DOAC concentrations.
Thromboplastin dilution enhances sensitivity to DOACs and heparins, enabling an inexpensive, easily implemented semi-quantitative DOAC assay, demonstrated and published by us 10 years ago (Loic Leterte et al, see headshot).
Would anyone be interested in a cheap DOAC assay applicable to coagulometers?”
Stay updated with Hemostasis Today.
-
Mar 13, 2026, 10:28Anupama Ariyasiri։ A Systematic Review of Transfusion Strategies in Neurocritical Care
-
Mar 13, 2026, 10:08Jack Hadfield: An Important Step Toward Finding Measurable Biology in Long COVID
-
Mar 13, 2026, 10:00Mandy Lauw: Can Reduced-Dose DOACs Be Applied to All Patients With VTE?
-
Mar 12, 2026, 20:44Honoring Marion Stolte’s Lasting Impact on the Bleeding Disorders Community – WFH
-
Mar 12, 2026, 20:37Paul Riley: Is Thrombin Generation Assay Ready for Prime Time?
-
Mar 12, 2026, 20:28Rob Maloney: Building Visibility for Bleeding Disorders in Rural Georgia
-
Mar 12, 2026, 20:19Akshat Jain: Validating Oral Pain Medication Use as a Global Marker in Sickle Cell Disease
-
Mar 12, 2026, 20:13Michael Makris: Early Clinical Results of AAV8-BDD FVIII Gene Therapy in Hemophilia A
-
Mar 12, 2026, 20:02Wolfgang Miesbach: From Heparin to Vaccines – The Expanding Biology of Anti-PF4 Immunothrombosis